Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06026254 · ClinicalTrials.gov registry record · Phase 1
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
A Phase 1 study of Solid Tumor, Adult, sponsored by ImmuneSensor Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT06026254: Active Phase 1 study of Solid Tumor, Adult, sponsored by ImmuneSensor Therapeutics.
NCT06026254 is a Phase 1 study of Solid Tumor, Adult that is active but no longer recruiting, run by ImmuneSensor Therapeutics. The registered enrollment target is 2 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06026254, a Phase 1 study of Solid Tumor, Adult, is active but no longer recruiting, sponsored by ImmuneSensor Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
Primary Outcome
Frequency of drug-related SAE by subject
Conditions Studied
Interventions
- DRUG IMSA101
- DRUG Immune Checkpoint Inhibitor
Study Locations (2)
Arizona
- Honor Health - Scottsdale
California
- UC San Diego Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2025-09 |
| Phase | Phase 1 |
What the registry record for NCT06026254 still lists
NCT06026254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which IMSA101 is the first listed.
NCT06026254 reports a single indexed study location in Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06026254 about?
NCT06026254 is a clinical study titled "A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial". This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
What is the current status of trial NCT06026254?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-09-15. Estimated completion is 2025-09.
What conditions does trial NCT06026254 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT06026254?
The interventions under investigation include: IMSA101 (DRUG), Immune Checkpoint Inhibitor (DRUG).
Who is sponsoring clinical trial NCT06026254?
This trial is sponsored by ImmuneSensor Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06026254 being conducted?
This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06026254's enrollment target sits among peer trials
2 73rd of 72 the lowest of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI